Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04811131 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo
A Phase 2 study, sponsored by Arcutis Biotherapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT04811131: Clinical Trial Phase 2 study, sponsored by Arcutis Biotherapeutics.
NCT04811131 is a Phase 2 study that was terminated before completion, run by Arcutis Biotherapeutics. The registered enrollment target is 114 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04811131, a Phase 2 study, was terminated before completion, sponsored by Arcutis Biotherapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of ARQ-252 cream in combination with NB-UVB phototherapy treatment in individuals with non-segmental facial vitiligo.
Primary Outcome
Achievement of F-VASI75 was declared with a ≥75% improvement from Baseline in F-VASI. F-VASI measures the % of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (none), 10% (only specks), 25% (pigmented area \> depigmented area), 50% (depigmented and pigmented areas equal), 75% (depigmented area \> pigmented area), 90% (specks of pigment), or 100% (no pigment). F-VASI was then derived by multiplying the values assessed for the vitiligo involvemen
Interventions
- DRUG ARQ-252 cream 0.3%
- DRUG ARQ-252 Vehicle cream
- DEVICE NB-UVB phototherapy active treatment
- DEVICE NB-UVB phototherapy sham treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2021-03-04 |
| Est. Completion | 2021-08-09 |
| Phase | Phase 2 |
Why NCT04811131 stopped before completion
NCT04811131 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower).
The record links to 0 conditions, and to 4 interventions - of which ARQ-252 cream 0.3% is the first listed.
NCT04811131 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04811131 about?
NCT04811131 is a clinical study titled "Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo". This study will assess the safety and efficacy of ARQ-252 cream in combination with NB-UVB phototherapy treatment in individuals with non-segmental facial vitiligo.
What is the current status of trial NCT04811131?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2021-03-04. Estimated completion is 2021-08-09.
What interventions are being tested in trial NCT04811131?
The interventions under investigation include: ARQ-252 cream 0.3% (DRUG), ARQ-252 Vehicle cream (DRUG), NB-UVB phototherapy active treatment (DEVICE), NB-UVB phototherapy sham treatment (DEVICE).
Who is sponsoring clinical trial NCT04811131?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04811131's enrollment target sits among peer trials
114 627th of 2000 higher than 1,370 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI